Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $1.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 4.90% from the company’s current price.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

A number of other research firms also recently commented on BLPH. ValuEngine downgraded Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 10th. Ladenburg Thalmann Financial Services began coverage on Bellerophon Therapeutics in a report on Monday, April 17th. They issued a “buy” rating and a $4.50 price objective for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $3.67.

Bellerophon Therapeutics (NASDAQ BLPH) traded up 0.70% during trading on Tuesday, hitting $1.43. The company had a trading volume of 113,946 shares. Bellerophon Therapeutics has a 12-month low of $0.43 and a 12-month high of $2.68. The company’s market capitalization is $47.17 million. The firm has a 50-day moving average of $1.38 and a 200 day moving average of $1.15.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. On average, equities research analysts forecast that Bellerophon Therapeutics will post ($0.98) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Lifted to Buy at Zacks Investment Research” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/11/bellerophon-therapeutics-inc-nasdaqblph-lifted-to-buy-at-zacks-investment-research.html.

A hedge fund recently raised its stake in Bellerophon Therapeutics stock. Renaissance Technologies LLC raised its stake in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 330.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 239,100 shares of the biotechnology company’s stock after buying an additional 183,600 shares during the period. Renaissance Technologies LLC owned approximately 1.65% of Bellerophon Therapeutics worth $124,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 42.51% of the company’s stock.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.